Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Pre-made Varlilumab benchmark antibody ( Whole mAb, anti-CD27 therapeutic antibody, Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-614
Pre-Made Varlilumab biosimilar, Whole mAb, Anti-CD27 Antibody: Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Varlilumab (INN; development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-614-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-614-10mg | 10mg | 21890 | ||
| GMP-Bios-ab-614-100mg | 100mg | 148000 | ||
| GMP-Bios-ab-614-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Varlilumab biosimilar, Whole mAb, Anti-CD27 Antibody: Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 therapeutic antibody |
| INN Name | Varlilumab |
| Target | CD27 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma |
| Conditions Discontinued | Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma |
| Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
